J. M. F. Niermeijer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
J. M. F. Niermeijer has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
H. Franssen
From the Rudolf Magnus Institute of Neuroscience, Department of Neurology (J.M.F.N., H.F., J.H.J.W., N.C.N.), and Julius Center for Health Services and Primary Care (K.F.), University Medical Center Utrecht, Utrecht; and Department of Neurology (M.E.), Spaarne Hospital, Hoofddorp, the Netherlands
3 shared publicationsJ. H.J. Wokke
From the Rudolf Magnus Institute of Neuroscience, Department of Neurology (J.M.F.N., H.F., J.H.J.W., N.C.N.), and Julius Center for Health Services and Primary Care (K.F.), University Medical Center Utrecht, Utrecht; and Department of Neurology (M.E.), Spaarne Hospital, Hoofddorp, the Netherlands
3 shared publicationsM. Eurelings
From the Rudolf Magnus Institute of Neuroscience, Department of Neurology (J.M.F.N., H.F., J.H.J.W., N.C.N.), and Julius Center for Health Services and Primary Care (K.F.), University Medical Center Utrecht, Utrecht; and Department of Neurology (M.E.), Spaarne Hospital, Hoofddorp, the Netherlands
3 shared publicationsN. C. Notermans
From the Rudolf Magnus Institute of Neuroscience, Department of Neurology (J.M.F.N., H.F., J.H.J.W., N.C.N.), and Julius Center for Health Services and Primary Care (K.F.), University Medical Center Utrecht, Utrecht; and Department of Neurology (M.E.), Spaarne Hospital, Hoofddorp, the Netherlands
3 shared publicationsJ H J Wokke
Department of Neurology and Rudolf Magnus Institute of Neurosciences, University Medical Center, Utrecht, The Netherlands
2 shared publications- Kathelijn Fischer
Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
2 shared publications
Latest Publications
- 2 February 2010
- Published by Wolters Kluwer Health in Neurology
- Vol. 74 (5) , 406-412
Prognosis of polyneuropathy due to IgM monoclonal gammopathy
Background: The disease course of polyneuropathy associated with immunoglobulin M monoclonal gammopathy (IgM MGUSP) can be highly variable. In order to identify factors that influence long-term disease outcome, a prospective cohort study was performed of 140 patients with IgM MGUSP over a period of 23 years. Methods: All patients with IgM MGUSP who were diagnosed in our tertiary referral center for polyneuropathy were eligible. All patients underwent nerve conduction studies and were tested for anti-MAG antibodies. The modified Rankin Scale, graded muscle strength, quantified sensory function, and laboratory testing were performed at 0, 1, 2, and 5 years and at last visit. The primary outcome measure was the risk of developing a modified Rankin Scale score of ≥3 points. Results: A total of 140 patients with IgM MGUSP fulfilled inclusion criteria (101 [72%] demyelinating, 39 [28%] axonal, 63 [44%] MAG positive). The median age at onset was 59 years (interquartile range 52–67), median disease duration at baseline was 3.2 years (interquartile range 1.9–6). Anti-MAG antibodies were associated with a lower risk of Rankin Scale score ≥3. Demyelination and a higher age at onset were associated with a higher risk for Rankin Scale score ≥3. Based on these 3 factors, a Web-based prognostic model was developed that directly allows clinicians to estimate the probability of developing disability (http://www.umcutrecht.nl/subsite/Prognosis-MGUS-Neuropathy). Conclusion: Higher age at onset and demyelination increase the risk, whereas anti-MAG antibodies decrease the risk, of developing Rankin Scale score ≥3 in polyneuropathy associated with immunoglobulin M monoclonal gammopathy (IgM MGUSP). Our Web-based prognostic model allows determination of prognosis in IgM MGUSP.
- 2 February 2010
- Published by Wolters Kluwer Health in Neurology
- Vol. 74 (5) , 406-412
Prognosis of polyneuropathy due to IgM monoclonal gammopathy
Background: The disease course of polyneuropathy associated with immunoglobulin M monoclonal gammopathy (IgM MGUSP) can be highly variable. In order to identify factors that influence long-term disease outcome, a prospective cohort study was performed of 140 patients with IgM MGUSP over a period of 23 years. Methods: All patients with IgM MGUSP who were diagnosed in our tertiary referral center for polyneuropathy were eligible. All patients underwent nerve conduction studies and were tested for anti-MAG antibodies. The modified Rankin Scale, graded muscle strength, quantified sensory function, and laboratory testing were performed at 0, 1, 2, and 5 years and at last visit. The primary outcome measure was the risk of developing a modified Rankin Scale score of ≥3 points. Results: A total of 140 patients with IgM MGUSP fulfilled inclusion criteria (101 [72%] demyelinating, 39 [28%] axonal, 63 [44%] MAG positive). The median age at onset was 59 years (interquartile range 52–67), median disease duration at baseline was 3.2 years (interquartile range 1.9–6). Anti-MAG antibodies were associated with a lower risk of Rankin Scale score ≥3. Demyelination and a higher age at onset were associated with a higher risk for Rankin Scale score ≥3. Based on these 3 factors, a Web-based prognostic model was developed that directly allows clinicians to estimate the probability of developing disability (http://www.umcutrecht.nl/subsite/Prognosis-MGUS-Neuropathy). Conclusion: Higher age at onset and demyelination increase the risk, whereas anti-MAG antibodies decrease the risk, of developing Rankin Scale score ≥3 in polyneuropathy associated with immunoglobulin M monoclonal gammopathy (IgM MGUSP). Our Web-based prognostic model allows determination of prognosis in IgM MGUSP.
- 14 August 2009
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 80 (9) , 1036-1039
Rituximab for polyneuropathy with IgM monoclonal gammopathy
Background: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment. Methods: In a prospective open label trial, 17 patients with disabling IgM MGUS polyneuropathy were treated with rituximab, a chimeric anti-CD-20 monoclonal antibody. Results: Rituximab induced an improvement of ⩾1 point on the Overall Disability Sum Score in 2/17 patients, an improvement of ⩾5% of the distal MRC sum score in 4/17 and the sensory sum score in 9/17 patients. Bone marrow investigations showed CD 20 B cell depletion in all patients. There were no serious adverse events. Compared with treatment with intermittent cyclophosphamide with prednisone or treatment with fludarabine, it shows a comparable response percentages but fewer side effects. The presence of anti-MAG and a disease duration shorter than 10 years may predict treatment response. Conclusion: Rituximab is a candidate for treatment of IgM MGUS polyneuropathy and should be further investigated in a double-blind randomised trial.
- 14 August 2009
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 80 (9) , 1036-1039
Rituximab for polyneuropathy with IgM monoclonal gammopathy
Background: Polyneuropathy with IgM monoclonal gammopathy can be a disabling disorder necessitating treatment. Methods: In a prospective open label trial, 17 patients with disabling IgM MGUS polyneuropathy were treated with rituximab, a chimeric anti-CD-20 monoclonal antibody. Results: Rituximab induced an improvement of ⩾1 point on the Overall Disability Sum Score in 2/17 patients, an improvement of ⩾5% of the distal MRC sum score in 4/17 and the sensory sum score in 9/17 patients. Bone marrow investigations showed CD 20 B cell depletion in all patients. There were no serious adverse events. Compared with treatment with intermittent cyclophosphamide with prednisone or treatment with fludarabine, it shows a comparable response percentages but fewer side effects. The presence of anti-MAG and a disease duration shorter than 10 years may predict treatment response. Conclusion: Rituximab is a candidate for treatment of IgM MGUS polyneuropathy and should be further investigated in a double-blind randomised trial.
- 15 November 2007
- Published by Springer Nature in Journal of Neurology
- Vol. 254 (12) , 1757-1758
Rapidly progressive coma, hydrocephalus and leukoencephalopathy as presenting features of leptomeningeal metastases
- 15 November 2007
- Published by Springer Nature in Journal of Neurology
- Vol. 254 (12) , 1757-1758
Rapidly progressive coma, hydrocephalus and leukoencephalopathy as presenting features of leptomeningeal metastases
- 3 July 2007
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (1) , 50-59
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy
Background: The best treatment for polyneuropathy associated with IgM monoclonal gammopathy (MGUS) is unknown. Oral cyclophosphamide combined with prednisone showed limited efficacy in a previous open label pilot study. We therefore performed a double-blind, randomized, placebo-controlled study of combined oral cyclophosphamide and prednisone in IgM MGUS polyneuropathy.
- 3 July 2007
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (1) , 50-59
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy
Background: The best treatment for polyneuropathy associated with IgM monoclonal gammopathy (MGUS) is unknown. Oral cyclophosphamide combined with prednisone showed limited efficacy in a previous open label pilot study. We therefore performed a double-blind, randomized, placebo-controlled study of combined oral cyclophosphamide and prednisone in IgM MGUS polyneuropathy.
- 12 December 2006
- Published by Wolters Kluwer Health in Neurology
- Vol. 67 (11) , 2076-2079
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy
A 58-year-old man with dizziness and unsteady gait had a 10-year history of behavioral change, impotence, and a progressive peripheral neuropathy. CT revealed low-density, contrast-enhancing lesions in the right pontine tegmentum and the right medial temporal lobe. Temporal lobe biopsy contained a collection of mature histiocytes, with PAS-positive rod-shaped inclusions. These inclusions, when studied by electronmicroscopy, were seen to be membrane-bound bacilliform bodies. Peroral jejunal biopsy contained no such inclusions. Despite treatment with antibiotics, the patient's neurologic illness progressed, and he succumbed to intercurrent sepsis. We believe this to be the first instance in which a lesion of Whipple disease has been identified within the CNS by CT scan, and the diagnosis made antemortem, in the absence of demonstrable systemic disease.
- 12 December 2006
- Published by Wolters Kluwer Health in Neurology
- Vol. 67 (11) , 2076-2079
Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy
A 58-year-old man with dizziness and unsteady gait had a 10-year history of behavioral change, impotence, and a progressive peripheral neuropathy. CT revealed low-density, contrast-enhancing lesions in the right pontine tegmentum and the right medial temporal lobe. Temporal lobe biopsy contained a collection of mature histiocytes, with PAS-positive rod-shaped inclusions. These inclusions, when studied by electronmicroscopy, were seen to be membrane-bound bacilliform bodies. Peroral jejunal biopsy contained no such inclusions. Despite treatment with antibiotics, the patient's neurologic illness progressed, and he succumbed to intercurrent sepsis. We believe this to be the first instance in which a lesion of Whipple disease has been identified within the CNS by CT scan, and the diagnosis made antemortem, in the absence of demonstrable systemic disease.
- 27 May 2006
- Vol. 150 (21) , 1173-8
[Clinical reasoning and decision-making in practice. A patient with loss of vision and painful legs].
A 69-year-old man was admitted to the Department of Ophthalmology with bilateral loss of vision. For a few months he had also had shooting pains in both legs and instability of gait. Neurological examination showed loss of vision bilaterally and minor sensory disturbances of the legs with diminished tendon reflexes. As extensive further examination showed no specific abnormalities, the tentative diagnosis 'arteriitis temporalis' was made. Despite treatment with corticosteroids his condition deteriorated. Only after a repeat medical history had been taken did it become clear that in the past he had had homosexual contact with a number of partners. This increased the likelihood of a sexually transmitted disease in the differential diagnosis. In the meantime the results from serological tests became known: there were strongly elevated titres for syphilis in both serum and cerebral spinal fluid. Eventually the patient was diagnosed with neurosyphilis with ocular involvement and tabes dorsalis. He recovered almost completely in a few months after treatment with doxycycline.
- 27 May 2006
- Vol. 150 (21) , 1173-8
[Clinical reasoning and decision-making in practice. A patient with loss of vision and painful legs].
A 69-year-old man was admitted to the Department of Ophthalmology with bilateral loss of vision. For a few months he had also had shooting pains in both legs and instability of gait. Neurological examination showed loss of vision bilaterally and minor sensory disturbances of the legs with diminished tendon reflexes. As extensive further examination showed no specific abnormalities, the tentative diagnosis 'arteriitis temporalis' was made. Despite treatment with corticosteroids his condition deteriorated. Only after a repeat medical history had been taken did it become clear that in the past he had had homosexual contact with a number of partners. This increased the likelihood of a sexually transmitted disease in the differential diagnosis. In the meantime the results from serological tests became known: there were strongly elevated titres for syphilis in both serum and cerebral spinal fluid. Eventually the patient was diagnosed with neurosyphilis with ocular involvement and tabes dorsalis. He recovered almost completely in a few months after treatment with doxycycline.